Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors.
Chronic obstructive pulmonary disease (COPD)
advanced lung cancer
immune checkpoint inhibitor (ICI)
interleukin-2R (IL-2R)
interleukin-8 (IL-8)
mixed ventilatory defect
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
entrez:
24
6
2021
pubmed:
25
6
2021
medline:
25
6
2021
Statut:
ppublish
Résumé
The coexistence of chronic obstructive pulmonary disease (COPD) in lung cancer patients often correlates with a poor clinical outcome regardless of tumor stage, mainly due to older age, poor lung function, and complex comorbid disease. Emerging data suggest that the pathogenesis of both diseases involves aberrant immune functioning. We conducted this retrospective study to describe the impact of COPD on the clinical outcomes of lung cancer patients treated with immunotherapy and investigate the potential prognostic factors. In total, 156 patients with advanced-stage lung cancer who received at least one administration of an anti-programmed cell death 1 (PD-1)/anti-programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitor (ICI) at any treatment line at Zhongshan Hospital Fudan University between May 2018 and December 2019 were enrolled in our study. Overall survival (OS) and progression-free survival (PFS) were analyzed according to the presence of COPD. We also evaluated the prognostic value of circulating cytokine levels for clinical outcome. We found that the presence of COPD (both spirometry-based COPD and physician-defined COPD) was significantly associated with longer PFS (316 COPD was associated with better survival in advanced-stage lung cancer patients treated with ICIs. Plasma IL-8 and IL-2R levels were potential prognostic factors for clinical outcome. The nomograms represent a possibly useful tool for predicting the clinical outcomes of immunotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
The coexistence of chronic obstructive pulmonary disease (COPD) in lung cancer patients often correlates with a poor clinical outcome regardless of tumor stage, mainly due to older age, poor lung function, and complex comorbid disease. Emerging data suggest that the pathogenesis of both diseases involves aberrant immune functioning. We conducted this retrospective study to describe the impact of COPD on the clinical outcomes of lung cancer patients treated with immunotherapy and investigate the potential prognostic factors.
METHODS
METHODS
In total, 156 patients with advanced-stage lung cancer who received at least one administration of an anti-programmed cell death 1 (PD-1)/anti-programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitor (ICI) at any treatment line at Zhongshan Hospital Fudan University between May 2018 and December 2019 were enrolled in our study. Overall survival (OS) and progression-free survival (PFS) were analyzed according to the presence of COPD. We also evaluated the prognostic value of circulating cytokine levels for clinical outcome.
RESULTS
RESULTS
We found that the presence of COPD (both spirometry-based COPD and physician-defined COPD) was significantly associated with longer PFS (316
CONCLUSIONS
CONCLUSIONS
COPD was associated with better survival in advanced-stage lung cancer patients treated with ICIs. Plasma IL-8 and IL-2R levels were potential prognostic factors for clinical outcome. The nomograms represent a possibly useful tool for predicting the clinical outcomes of immunotherapy.
Identifiants
pubmed: 34164266
doi: 10.21037/tlcr-21-214
pii: tlcr-10-05-2148
pmc: PMC8182718
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2148-2162Informations de copyright
2021 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr-21-214). The authors have no conflicts of interest to declare.
Références
BMC Cancer. 2016 Jul 20;16:505
pubmed: 27439430
Nat Med. 2020 May;26(5):693-698
pubmed: 32405063
Am J Respir Crit Care Med. 2011 Oct 15;184(8):913-9
pubmed: 21799072
Int J Cancer. 2019 Nov 1;145(9):2433-2439
pubmed: 30807641
Carcinogenesis. 2020 Nov 13;41(11):1518-1528
pubmed: 32602900
Am J Respir Crit Care Med. 2014 Jul 1;190(1):40-50
pubmed: 24825462
J Clin Oncol. 2005 May 10;23(14):3175-85
pubmed: 15886304
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Cancer Res. 2011 Aug 1;71(15):5296-306
pubmed: 21653678
Thorax. 2010 Oct;65(10):903-7
pubmed: 20861294
Clin Cancer Res. 2016 Aug 1;22(15):3924-36
pubmed: 26957562
Vaccines (Basel). 2016 Jun 24;4(3):
pubmed: 27348007
Respirology. 2016 Feb;21(2):269-79
pubmed: 26567533
Am J Respir Crit Care Med. 2018 Oct 1;198(7):928-940
pubmed: 29518341
Cancer Immunol Res. 2015 Dec;3(12):1344-55
pubmed: 26253731
PLoS One. 2015 Nov 10;10(11):e0142306
pubmed: 26555338
J Transl Med. 2017 Mar 24;15(1):65
pubmed: 28340574
Chest. 2014 Feb;145(2):346-353
pubmed: 24008835
Ann Am Thorac Soc. 2015 Nov;12 Suppl 2:S169-75
pubmed: 26595735
Multidiscip Respir Med. 2017 Feb 9;12:3
pubmed: 28194273
Eur Respir J. 2016 Dec;48(6):1743-1750
pubmed: 27811074
Yonsei Med J. 2016 Sep;57(5):1063-9
pubmed: 27401635
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Eur Respir J. 2009 Aug;34(2):380-6
pubmed: 19196816
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
Int J Chron Obstruct Pulmon Dis. 2018 Jul 12;13:2139-2146
pubmed: 30034229
Expert Opin Ther Targets. 2019 Jun;23(6):539-553
pubmed: 31079559
Am J Respir Crit Care Med. 2018 Feb 1;197(3):325-336
pubmed: 28934595
J Clin Invest. 1989 Oct;84(4):1045-9
pubmed: 2677047
Nat Rev Immunol. 2018 Oct;18(10):648-659
pubmed: 30089912